Italian family-controlled global pharmaceutical company established in 1935, headquartered in Parma; specializes in respiratory, neonatology and rare disease medicines, operating through 31 affiliates with products available in around 100 countries. Not publicly listed.
相关临床试验
495
292 进行中
药物批准
82
批准总数
监管机构
6
监管机构数
成立时间
1935
进行中（未招募）
288
58.2%
Approved For Marketing
1
0.2%
Available
1
0.2%
已完成
148
29.9%
尚未招募
4
0.8%
招募中
34
6.9%
终止
15
3.0%
撤回
4
0.8%
- Veld Pharmaceuticals GmbH and Chiesi Farmaceutici S.p.A have announced a collaboration to expand patient access to nine rare-disease therapies through a Managed Access Program across Africa. - The program enables physicians to prescribe therapies to patients with serious unmet medical needs who meet defined medical eligibility criteria and have appropriate funding mechanisms in place. - Veld will administer the program and facilitate access to Chiesi's rare-disease therapies on a named-patient basis, ensuring full compliance with local regulatory, ethical, and pharmacovigilance requirements. - The collaboration aims to ensure that patients with the highest unmet needs are no longer defined by geography while maintaining the highest standards of regulatory compliance and patient safety.
- The FDA has accepted Chiesi's New Drug Application for its investigational triple combination inhaler containing beclomethasone dipropionate, formoterol fumarate, and glycopyrrolate for maintenance treatment of asthma in adults. - The single inhaler triple therapy was the world's first fixed triple combination in a single inhaler and is already commercialized in nearly 50 countries outside the U.S., including the European Union, United Kingdom, and China. - Clinical data supporting the NDA comes from the TRIMARAN and TRIGGER Phase 3 trials, which evaluated safety and efficacy in more than 2,500 patients with uncontrolled asthma. - This regulatory milestone addresses a significant unmet need, as an estimated 60% of adults with asthma continue to experience frequent symptoms despite existing treatments, with asthma costing the U.S. an estimated $82 billion annually.
- Elgan Pharma and Chiesi Group have dosed the first patients in FIT-PIV, a Phase 3 trial evaluating ELGN-2112 for intestinal malabsorption in preterm infants. - The study will enroll 420 infants born at 26-32 weeks gestation across 50 sites in the UK, Europe, Israel and the United States. - ELGN-2112 is a proprietary recombinant human insulin formulation designed to improve gastrointestinal function and reduce complications in premature babies. - Previous trials showed infants treated with ELGN-2112 reached nutrition goals earlier and had shorter parenteral nutrition requirements with fewer complications.
